Syndecan-1-dependent suppression of PDK1/Akt/Bad signaling by docosahexaenoic acid induces apoptosis in prostate cancer

Neoplasia

Volumn 12, Issue 10, 2010, Pages 826-836

  Hu, Yunping ^a   Sun, Haiguo ^a   Owens, Rick T ^b   Gu, Zhennan ^a   Wu, Jansheng ^a   Chen, Yong Q ^a   O'Flaherty, Joseph T ^a   Edwards, Iris J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b LIFECELL CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN BAD; PROTEIN KINASE B; SMALL INTERFERING RNA; SYNDECAN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL STRAIN LNCAP; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 77957807607     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10586     Document Type: Article

References (62)

1. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, et al. (1977). Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 20, 680-688.
2. Parkin DM, Bray F, Ferlay J, and Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin 55, 74-108.
3. Armstrong B and Doll R (1975). Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 15, 617-631.
4. Haenszel W and Kurihara M (1968). Studies of Japanese migrants: I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 40, 43-68.
5. Yang YJ, Lee SH, Hong SJ, and Chung BC (1999). Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia. Clin Biochem 32, 405-409.
6. Mamalakis G, Kafatos A, Kalogeropoulos N, Andrikopoulos N, Daskalopulos G, and Kranidis A (2002). Prostate cancer vs hyperplasia: relationships with prostatic and adipose tissue fatty acid composition. Prostaglandins Leukot Essent Fatty Acids 66, 467-477.
7. Freeman VL, Meydani M, Hur K, and Flanigan RC (2004). Inverse association between prostatic polyunsaturated fatty acid and risk of locally advanced prostate carcinoma. Cancer 101, 2744-2754.
8. Rose DP and Connolly JM (1991). Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate 18, 243-254.
9. Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Cohen P, Leung P, Hong-Gonzalez J, Freedland SJ, Said J, et al. (2006). Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res 12, 4662-4670.
10. Berquin IM, Min Y, Wu R, Wu J, Perry D, Cline JM, Thomas MJ, Thornburg T, Kulik G, Smith A, et al. (2007). Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest 117, 1866-1875.
11. Larsson SC, Kumlin M, Ingelman-Sundberg M, andWolk A (2004).Dietary longchain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 79, 935-945.
12. Berquin IM, Edwards IJ, and Chen YQ (2008). Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett 269, 363-377.
13. Liebersbach BF and Sanderson RD (1994). Expression of syndecan-1 inhibits cell invasion into type I collagen. J Biol Chem 269, 20013-20019.
14. Liu W, Litwack ED, Stanley MJ, Langford JK, Lander AD, and Sanderson RD (1998). Heparan sulfate proteoglycans as adhesive and anti-invasive molecules. Syndecans and glypican have distinct functions. J Biol Chem 273, 22825-22832.
15. Couchman JR (2003). Syndecans: proteoglycan regulators of cell-surface microdomains? Nat Rev Mol Cell Biol 4, 926-937.
16. Inki P and Jalkanen M (1996). The role of syndecan-1 in malignancies. Ann Med 28, 63-67.
17. Perrimon N and Bernfield M (2000). Specificities of heparan sulphate proteoglycans in developmental processes. Nature 404, 725-728.
18. Rapraeger AC (2001). Molecular interactions of syndecans during development. Semin Cell Dev Biol 12, 107-116.
19. Li Q, Park PW, Wilson CL, and Parks WC (2002). Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111, 635-646.
20. Endo K, Takino T, Miyamori H, Kinsen H, Yoshizaki T, Furukawa M, and Sato H (2003). Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem 278, 40764-40770.
21. Brule S, Charnaux N, Sutton A, Ledoux D, Chaigneau T, Saffar L, and Gattegno L (2006). The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology 16, 488-501.
22. Hashimoto Y, Skacel M, and Adams JC (2008). Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors. BMC Cancer 8, 185.
23. Kato M, Saunders S, Nguyen H, and Bernfield M (1995). Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchymelike cells.Mol Biol Cell 6, 559-576.
24. Loussouarn D, Campion L, Sagan C, Frenel JS, Dravet F, Classe JM, Pioud- Martigny R, Berton-Rigaud D, Bourbouloux E, Masnier JF, et al. (2008). Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. Br J Cancer 98, 1993-1998.
25. Purushothaman A, Chen L, Yang Y, and Sanderson RD (2008). Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem 283, 32628-32636.
26. Leppa S, Mali M, Miettinen HM, and Jalkanen M (1992). Syndecan expression regulates cell morphology and growth of mouse mammary epithelial tumor cells. Proc Natl Acad Sci USA 89, 932-936.
27. Contreras HR, Ledezma RA, Vergara J, Cifuentes F, Barra C, Cabello P, Gallegos I, Morales B, Huidobro C, and Castellon E (in press). The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and β-catenin, in prostate cancer. Urol Oncol.
28. Kiviniemi J, Kallajoki M, Kujala I, Matikainen MT, Alanen K, Jalkanen M, and Salmivirta M (2004). Altered expression of syndecan-1 in prostate cancer. APMIS 112, 89-97.
29. Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, Swindell R, Slade RJ, Martin-Hirsch P, Gallagher JT, and Jayson GC (2004). Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res 10, 5178-5186.
30. Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, Veronese S, Caffo O, Lucenti A, Palma D, et al. (2003). High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 98, 474-483.
31. Conejo JR, Kleeff J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, Bicheng N, Zimmermann A, Korc M, Friess H, et al. (2000). Syndecan-1 expression is upregulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer 88, 12-20.
32. Choi DS, Kim JH, Ryu HS, Kim HC, Han JH, Lee JS, and Min CK (2007). Syndecan-1, a key regulator of cell viability in endometrial cancer. Int J Cancer 121, 741-750.
33. Watanabe A, Mabuchi T, Satoh E, Furuya K, Zhang L, Maeda S, and Naganuma H (2006). Expression of syndecans, a heparan sulfate proteoglycan, in malignant gliomas: participation of nuclear factor-κB in upregulation of syndecan-1 expression. J Neurooncol 77, 25-32.
34. Nikolova V, Koo CY, Ibrahim SA, Wang Z, Spillmann D, Dreier R, Kelsch R, Fischgrabe J, Smollich M, Rossi LH, et al. (2009). Differential roles for membranebound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 30, 397-407.
35. Edwards IJ, Sun H, Hu Y, Berquin IM, O'Flaherty JT, Cline JM, Rudel LL, and Chen YQ (2008). In vivo and in vitro regulation of syndecan 1 in prostate cells by n-3 polyunsaturated fatty acids. J Biol Chem 283, 18441-18449.
36. Edwards IJ, Berquin IM, Sun H, O'Flaherty JT, Daniel LW, Thomas MJ, Rudel LL, Wykle RL, and Chen YQ (2004). Differential effects of delivery of omega-3 fatty acids to human cancer cells by low-density lipoproteins versus albumin. Clin Cancer Res 10, 8275-8283.
37. Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H, Liu X, and Wu H (2002). Cre/loxP-mediated inactivation of themurine Pten tumor suppressor gene. Genesis 32, 148-149.
38. Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ, Sangiorgi FO, Maxson RE, Sucov HM, and Roy-Burman P (2001). Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 101, 61-69.
39. Sun H, Berquin IM, Owens RT, O'Flaherty JT, and Edwards IJ (2008). Peroxisome proliferator-activated receptor gamma-mediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells. Cancer Res 68, 2912-2919.
40. Hu Y, Sun H, Owens RT, Wu J, Chen YQ, Berquin IM, Perry D, O'Flaherty JT, and Edwards IJ (2009). Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia 11, 1042-1053.
41. Sun H, Berquin IM, and Edwards IJ (2005). omega-3 polyunsaturated fatty acids regulate syndecan-1 expression in human breast cancer cells. Cancer Res 65, 4442-4447.
42. Dibble CC and Manning BD (2009). A molecular link between AKTregulation and chemotherapeutic response. Cancer Cell 16, 178-180.
43. Guertin DA and Sabatini DM (2007). Defining the role of mTOR in cancer. Cancer Cell 12, 9-22.
44. Manning BD and Cantley LC (2007). AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274.
45. Osaki M, Oshimura M, and Ito H (2004). PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9, 667-676.
46. Smith AJ, Karpova Y, D'Agostino R Jr, Willingham M, and Kulik G (2009). Expression of the Bcl-2 protein BAD promotes prostate cancer growth. PLoS One 4, e6224.
47. Feldman BJ and Feldman D (2001). The development of androgen-independent prostate cancer. Nat Rev Cancer 1, 34-45.
48. Wu X, Kan M, Wang F, Jin C, Yu C, and McKeehan WL (2001). A rare premalignant prostate tumor epithelial cell syndecan-1 forms a fibroblast growth factor-binding complex with progression-promoting ectopic fibroblast growth factor receptor 1. Cancer Res 61, 5295-5302.
49. Chavarro JE, Stampfer MJ, Hall MN, Sesso HD, and Ma J (2008). A 22-y prospective study of fish intake in relation to prostate cancer incidence and mortality. Am J Clin Nutr 88, 1297-1303.
50. Leitzmann MF, Stampfer MJ, Michaud DS, Augustsson K, Colditz GC, Willett WC, and Giovannucci EL (2004).Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer. Am J Clin Nutr 80, 204-216.
51. Norrish AE, Skeaff CM, Arribas GL, Sharpe SJ, and Jackson RT (1999). Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. Br J Cancer 81, 1238-1242.
52. Terry P, Lichtenstein P, Feychting M, Ahlbom A, and Wolk A (2001). Fatty fish consumption and risk of prostate cancer. Lancet 357, 1764-1766.
53. Freeman VL, Meydani M, Yong S, Pyle J, Flanigan RC, Waters WB, and Wojcik EM (2000). Prostatic levels of fatty acids and the histopathology of localized prostate cancer. J Urol 164, 2168-2172.
54. Ritch CR, Brendler CB, Wan RL, Pickett KE, and Sokoloff MH (2004). Relationship of erythrocyte membrane polyunsaturated fatty acids and prostate-specific antigen levels in Jamaican men. BJU Int 93, 1211-1215.
55. Mali M, Elenius K, Miettinen HM, and Jalkanen M (1993). Inhibition of basic fibroblast growth factor-induced growth promotion by overexpression of syndecan-1. J Biol Chem 268, 24215-24222.
56. Sasisekharan R, Shriver Z, Venkataraman G, and Narayanasami U (2002). Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2, 521-528.
57. Deepa SS, Yamada S, Zako M, Goldberger O, and Sugahara K (2004). Chondroitin sulfate chains on syndecan-1 and syndecan-4 from normal murine mammary gland epithelial cells are structurally and functionally distinct and cooperate with heparan sulfate chains to bind growth factors. A novel function to control binding of midkine, pleiotrophin, and basic fibroblast growth factor. J Biol Chem 279, 37368-37376.
58. Dhodapkar MV, Abe E, Theus A, Lacy M, Langford JK, Barlogie B, and Sanderson RD (1998). Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood 91, 2679-2688.
59. Fayard E, Tintignac LA, Baudry A, and Hemmings BA (2005). Protein kinase B/Akt at a glance. J Cell Sci 118, 5675-5678.
60. Sarker D, Reid AH, Yap TA, and de Bono JS (2009). Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 15, 4799-4805.
61. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J, and Rosen N (2005). The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8, 287-297.
62. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, and Greenberg ME (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231-241.